{"product_id":"organigram-business-model-canvas","title":"Organigram Holdings Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganigram's Business Model Unveiled\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Organigram Holdings's business model. This in-depth Business Model Canvas reveals how the company drives value, captures market share, and stays ahead in a competitive landscape. Ideal for entrepreneurs, consultants, and investors looking for actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBritish American Tobacco (BAT)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganigram Holdings benefits immensely from its key partnership with British American Tobacco (BAT). This collaboration isn't just about investment; it's a deep dive into product innovation, specifically targeting the development of next-generation non-combustible cannabis products. This strategic alliance leverages BAT's global reach and expertise in consumer goods alongside Organigram's cannabis product development capabilities.\u003c\/p\u003e\n\u003cp\u003eA cornerstone of this partnership is BAT's significant equity investment. Notably, BAT made a substantial follow-on investment of $124.6 million during the 2024-2025 period. This influx of capital is crucial for Organigram, fueling its expansion into new markets and supporting its ongoing growth initiatives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProvincial Cannabis Boards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProvincial cannabis boards are essential partners for Organigram, acting as the primary gatekeepers for distributing recreational cannabis products throughout Canada.\u003c\/p\u003e\n\u003cp\u003eOrganigram actively collaborates with these governmental bodies to navigate complex regulatory frameworks, ensuring all products meet stringent compliance standards. This close working relationship is vital for Organigram to gain access to the vast Canadian recreational market.\u003c\/p\u003e\n\u003cp\u003eThese partnerships represent a crucial distribution channel, allowing Organigram to reach a wide consumer base and ensure broad product availability across the country.\u003c\/p\u003e\n\u003cp\u003eFor instance, in 2024, Organigram's significant presence in key provincial markets demonstrates the effectiveness of these relationships. The company continues to leverage these provincial boards to expand its market reach and solidify its position in the Canadian cannabis industry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Supply Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganigram has strategically broadened its reach by forging supply agreements with partners in crucial international markets. These include significant inroads into Germany, the UK, Australia, and Israel, demonstrating a clear commitment to global expansion. These alliances are fundamental to accelerating international sales and solidifying Organigram’s position as a prominent player in the worldwide cannabis industry.\u003c\/p\u003e\n\u003cp\u003eThe company's proactive approach involves continuously assessing new global partnership prospects. This ongoing evaluation is key to furthering its international growth trajectory and capitalizing on emerging market opportunities. For instance, in fiscal year 2023, Organigram reported a substantial increase in its international revenue, largely attributed to these strategic supply agreements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSanity Group (Germany)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganigram Holdings' strategic partnership with Sanity Group, a prominent German cannabis cultivator and distributor, is pivotal for accessing the burgeoning European medical cannabis market. Organigram's $21 million investment in Sanity Group in early 2024 solidified this relationship, aiming to capitalize on Germany's expanding medical cannabis program.\u003c\/p\u003e\n\u003cp\u003eThis collaboration is built upon an existing supply agreement, with Organigram anticipating a substantial increase in its cannabis exports to Germany. The German market represents a significant growth opportunity, and Sanity Group’s established infrastructure and market knowledge are invaluable assets.\u003c\/p\u003e\n\u003cp\u003eFurther enhancing this partnership is Organigram's ongoing efforts to achieve EU Good Manufacturing Practice (EU-GMP) certification. This certification is crucial for enabling direct, compliant exports of cannabis products into Germany and other European Union member states, streamlining market entry and ensuring product quality standards are met.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSanity Group Partnership:\u003c\/strong\u003e Strategic investment of $21 million by Organigram Holdings to secure a foothold in the German medical cannabis market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Expansion:\u003c\/strong\u003e Leverages Sanity Group's position to increase Organigram's cannabis export volumes to Germany.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Compliance:\u003c\/strong\u003e Organigram's pursuit of EU-GMP certification facilitates direct exports, adhering to stringent European quality standards.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEuropean Focus:\u003c\/strong\u003e The partnership underscores Organigram's commitment to expanding its presence across the European continent.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMotif Labs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrganigram Holdings' acquisition of Motif Labs in December 2024 was a pivotal partnership, significantly enhancing its processing capacity and expanding its offerings, especially in the burgeoning cannabis 2.0 product sector. This strategic move propelled Organigram to become Canada's largest cannabis company based on market share. The integration of Motif Labs is anticipated to foster margin expansion through achieving economies of scale and better absorption of fixed costs, while also generating considerable cost synergies.\u003c\/p\u003e\n\u003cp\u003eThe key benefits derived from this partnership include:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eEnhanced Processing Capabilities:\u003c\/strong\u003e Motif Labs brought advanced extraction and product formulation expertise, boosting Organigram's ability to create a wider range of high-quality cannabis products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Leadership:\u003c\/strong\u003e The acquisition solidified Organigram's position as the leading cannabis company in Canada by market share, providing a significant competitive advantage.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSynergistic Cost Savings:\u003c\/strong\u003e Organigram projected substantial cost synergies from the integration, aiming for improved operational efficiency and profitability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct Portfolio Diversification:\u003c\/strong\u003e The partnership expanded Organigram's product line, particularly in the high-growth category of cannabis 2.0 products, catering to evolving consumer preferences.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances Drive Market Expansion and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganigram's key partnerships are fundamental to its operational success and market expansion. The collaboration with British American Tobacco (BAT) provides not only significant financial backing, with a $124.6 million follow-on investment in 2024-2025, but also access to global expertise. Provincial cannabis boards are essential distribution channels, ensuring Organigram's products reach consumers across Canada, a relationship vital for market penetration, as evidenced by Organigram's strong 2024 presence in these markets.\u003c\/p\u003e\n\u003cp\u003eThe company's strategic alliances extend internationally, with supply agreements in Germany, the UK, Australia, and Israel contributing to a notable increase in international revenue in fiscal year 2023. A key example is the $21 million investment in Germany's Sanity Group in early 2024, aimed at tapping into the European medical cannabis market, with Organigram pursuing EU-GMP certification to facilitate direct exports.\u003c\/p\u003e\n\u003cp\u003eFurthermore, the December 2024 acquisition of Motif Labs significantly bolstered Organigram's processing capabilities and market share, positioning it as Canada's largest cannabis company. This integration is expected to drive margin expansion and cost synergies, particularly in the high-growth cannabis 2.0 product sector.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnership Type\u003c\/td\u003e\n\u003ctd\u003eKey Partner\u003c\/td\u003e\n\u003ctd\u003eStrategic Importance\u003c\/td\u003e\n\u003ctd\u003eFinancial Impact \/ Investment\u003c\/td\u003e\n\u003ctd\u003eMarket Reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquity Investment \u0026amp; Product Development\u003c\/td\u003e\n\u003ctd\u003eBritish American Tobacco (BAT)\u003c\/td\u003e\n\u003ctd\u003eGlobal expertise, next-gen product innovation\u003c\/td\u003e\n\u003ctd\u003e$124.6 million follow-on investment (2024-2025)\u003c\/td\u003e\n\u003ctd\u003eGlobal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003eProvincial Cannabis Boards\u003c\/td\u003e\n\u003ctd\u003eAccess to Canadian recreational market\u003c\/td\u003e\n\u003ctd\u003eN\/A (regulatory access)\u003c\/td\u003e\n\u003ctd\u003eCanada\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply Agreements\u003c\/td\u003e\n\u003ctd\u003eGermany, UK, Australia, Israel\u003c\/td\u003e\n\u003ctd\u003eInternational sales acceleration\u003c\/td\u003e\n\u003ctd\u003eN\/A (revenue generation)\u003c\/td\u003e\n\u003ctd\u003eInternational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Acquisition\u003c\/td\u003e\n\u003ctd\u003eMotif Labs\u003c\/td\u003e\n\u003ctd\u003eProcessing capacity, market share, cannabis 2.0\u003c\/td\u003e\n\u003ctd\u003eAcquisition in December 2024\u003c\/td\u003e\n\u003ctd\u003eCanada (largest by market share)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Entry \u0026amp; Supply\u003c\/td\u003e\n\u003ctd\u003eSanity Group (Germany)\u003c\/td\u003e\n\u003ctd\u003eEuropean medical cannabis market\u003c\/td\u003e\n\u003ctd\u003e$21 million investment (early 2024)\u003c\/td\u003e\n\u003ctd\u003eGermany \/ Europe\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOrganigram Holdings' Business Model Canvas is a detailed blueprint for their strategy in the Canadian cannabis market, focusing on their cultivation, processing, and distribution of high-quality cannabis products.\u003c\/p\u003e\n\u003cp\u003eIt comprehensively outlines their target customer segments, diverse distribution channels, and unique value propositions, reflecting their operational approach and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOrganigram Holdings' Business Model Canvas acts as a pain point reliever by offering a clear, one-page snapshot of their operations, simplifying complex strategies for stakeholders and facilitating targeted problem-solving within the cannabis industry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCannabis Cultivation and Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganigram's primary activities center on the meticulous indoor cultivation of premium cannabis. This involves the precise management of sophisticated grow room environments to maximize yield per plant and consistently produce flower with elevated THC concentrations.\u003c\/p\u003e\n\u003cp\u003eThe company is strategically adopting seed-based cultivation methods to enhance operational efficiency and drive down production costs. Organigram aims for approximately 20% of its total harvests to originate from seed-based operations by fiscal year 2025, a move designed to streamline the growing process and improve cost-effectiveness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Development and Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOrganigram Holdings actively pursues product development and innovation, expanding its diverse portfolio to include dried flower, pre-rolls, edibles, vapes, and concentrates. This commitment is fueled by consumer insight-driven research and development.\u003c\/p\u003e\n\u003cp\u003eA prime example of this innovation is the introduction of the Edison Sonics line, featuring proprietary FAST nanoemulsion technology designed for quicker onset. This focus on advanced delivery systems directly addresses evolving consumer demand for faster-acting products.\u003c\/p\u003e\n\u003cp\u003eIn its fiscal year 2024, Organigram reported a significant increase in its cannabis 2.0 product revenue, driven by strong performance in its edibles and vapes segments. This growth underscores the success of their innovative product development strategies in capturing market share.\u003c\/p\u003e\n\u003cp\u003eThe company continuously aims to meet changing consumer preferences and maintain a competitive edge by introducing novel product offerings and enhancing existing categories, ensuring relevance in the dynamic cannabis market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Development and Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganigram Holdings is deeply invested in brand development, cultivating a diverse portfolio of adult-use recreational cannabis brands. Key players in their stable include Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, and Monjour. This multi-brand strategy allows Organigram to target specific consumer segments with tailored product offerings and distinct marketing campaigns, aiming to capture broader market share and foster brand loyalty.\u003c\/p\u003e\n\u003cp\u003eThe company's marketing efforts are designed to resonate with these segmented audiences, creating unique brand identities that stand out in a competitive landscape. For instance, SHRED is known for its focus on value and innovation in the dried flower category, while Edison appeals to a more discerning consumer seeking premium quality. This approach is essential for building brand recognition and driving sales growth.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Organigram continued to refine its brand positioning. The company reported that its SHRED brand, in particular, has seen significant success, contributing substantially to its revenue streams. This highlights the effectiveness of their strategy in creating brands that not only appeal to consumers but also translate into strong financial performance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganigram's distribution strategy focuses on leveraging provincial cannabis boards for the Canadian recreational market. This approach ensures wide product availability across regulated retail channels. For medical cannabis, Organigram engages in direct-to-consumer sales, providing a more personalized experience. \u003c\/p\u003e\n\u003cp\u003eThe company also actively participates in wholesale activities, supplying a diverse range of cannabis products to other retailers and wholesalers. This expands their reach beyond direct provincial contracts. In the fiscal year 2024, Organigram reported net revenue of $141.6 million, reflecting the strength of these distribution channels. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eProvincial Distribution:\u003c\/strong\u003e Primary channel for Canadian recreational market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDirect-to-Consumer:\u003c\/strong\u003e Focus for the Canadian medical cannabis market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWholesale:\u003c\/strong\u003e Supplying products to other retailers and wholesalers.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInternational Expansion:\u003c\/strong\u003e Growing through supply agreements and strategic foreign investments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eInternational sales represent a significant growth avenue for Organigram. The company is actively pursuing this by establishing supply agreements and making strategic investments in key foreign markets. This global push aims to diversify revenue streams and capitalize on evolving international cannabis regulations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisitions and International Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOrganigram Holdings strategically targets acquisitions to broaden its product offerings and operational scale. A prime example is its acquisition of The Edibles \u0026amp; Infusions Company (EIC), which bolstered its edibles portfolio.  Furthermore, its acquisition of Trai, a leading Canadian producer of infused beverages, significantly enhanced its beverage capabilities.\u003c\/p\u003e\n\u003cp\u003eThe company is actively pursuing international growth, with a keen focus on Germany and the United States. Organigram has established a joint venture with Windsor, Germany-based Psyre, to manufacture and distribute its cannabis products in the German medical market. This strategic move aims to tap into the burgeoning European cannabis market.\u003c\/p\u003e\n\u003cp\u003eOrganigram's expansion strategy includes building a robust international presence through key investments and partnerships. The company's focus on markets like Germany, which has shown significant growth in medical cannabis, underscores its commitment to global reach.  For instance, by the end of fiscal 2023, Organigram had made significant progress in its international strategy, with a particular emphasis on establishing a foothold in key European markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAcquisition of EIC:\u003c\/strong\u003e Strengthened edibles product line.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAcquisition of Trai:\u003c\/strong\u003e Enhanced cannabis beverage capabilities.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePsyre Joint Venture:\u003c\/strong\u003e Entry into the German medical cannabis market.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFocus on Germany and U.S.:\u003c\/strong\u003e Key targets for international expansion.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Cannabis Strategy Delivers Strong Financial Results\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOrganigram's key activities encompass the cultivation of cannabis, product development across various formats like edibles and vapes, and robust brand building for recreational markets. The company also focuses on distribution through provincial channels and direct-to-consumer sales for medical cannabis, alongside wholesale operations. Strategic international expansion and targeted acquisitions further define its operational scope.\u003c\/p\u003e\n\u003cp\u003eIn fiscal year 2024, Organigram reported net revenue of $141.6 million, underscoring the effectiveness of its diverse business activities and distribution networks in a competitive market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Activity\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003eFiscal Year 2024 Data\/Impact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCultivation\u003c\/td\u003e\n\u003ctd\u003eIndoor cultivation of premium cannabis, focusing on yield and THC concentration.\u003c\/td\u003e\n\u003ctd\u003eStrategic adoption of seed-based cultivation targeting 20% of harvests by FY2025 for efficiency.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Development\u003c\/td\u003e\n\u003ctd\u003eInnovation in dried flower, pre-rolls, edibles, vapes, and concentrates.\u003c\/td\u003e\n\u003ctd\u003eStrong growth in Cannabis 2.0 revenue, particularly from edibles and vapes. Introduction of Edison Sonics with FAST nanoemulsion technology.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand Development\u003c\/td\u003e\n\u003ctd\u003eCultivating diverse adult-use recreational cannabis brands.\u003c\/td\u003e\n\u003ctd\u003eSuccess of brands like SHRED contributing substantially to revenue. Portfolio includes Edison, Holy Mountain, Big Bag O' Buds, etc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003eLeveraging provincial boards for recreational, direct-to-consumer for medical, and wholesale.\u003c\/td\u003e\n\u003ctd\u003eNet revenue of $141.6 million in FY2024 reflects strong channel performance.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Expansion \u0026amp; Acquisitions\u003c\/td\u003e\n\u003ctd\u003ePursuing global growth through supply agreements, investments, and acquisitions.\u003c\/td\u003e\n\u003ctd\u003eJoint venture with Psyre for German market entry. Acquisitions of EIC and Trai bolstered edibles and beverage capabilities.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Organigram Holdings Business Model Canvas preview you see is the actual, unedited document you will receive upon purchase. This means all sections, including key partners, value propositions, customer relationships, revenue streams, key resources, activities, channels, cost structure, and customer segments, are presented exactly as they will be delivered. You are viewing a direct snapshot of the complete file, ensuring no discrepancies between the preview and your purchased product, ready for immediate use and analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55480525521273,"sku":"organigram-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/organigram-business-model-canvas.png?v=1752754858","url":"https:\/\/growthsharematrix.com\/products\/organigram-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}